be_ixf;ym_202410 d_13; ct_50

Latest Insights on ADI

omicron Adagio Therapeutics A Stock-Picking Mutation to Beat the Omicron Threat This is a company that has never made a profit. In fact, it’s never made any money at all. On top of that, analysts expect its per-share losses to double by the end of 2022. Assuming Adagio manages to generate some revenues next year — the market consensus is a minuscule $151 million — it’s already trading at almost 20 times those sales. Why? Because COVID is here to stay … and the search for a response is moving into new areas … quickly.
Two ETF Trades to Beat the Market in December Two ETF Trades to Beat the Market in December It's a new month, which means two free ETF trades from Mike Carr! This time, IWY and XSD ranked at the top of his list...
GM Tesla Hello There Star Wars Meme GM’s EV Fantasy, Airlines Knocked For A Loop & Dorsey Dumps Twitter
by Joseph Hargett November 29, 2021 Great Stuff
GM: General Misunderstanding Welcome back, Great Ones! I hope you had a great Thanksgiving break and that you didn’t miss this weekend’s Great Stuff Picks portfolio update. If you did, hurry up and click here to check it out now! I’ll wait… All done? Good. Now, today, we’re going to talk about the great electric […]
2022 stock predictions 5 Bold Predictions for 2022 and Beyond These will be the biggest growth themes for 2022.
Unusual Options Activity: A Black Friday Shopping Spree Unusual Options Activity: A Black Friday Shopping Spree As the market panicked in response to the Omicron variant, Big Money poured millions into bullish bets on individual stocks...

Newsletter Sign Up

Sponsored

CS Care Video

MEET OUR EXPERTS

WHAT READERS ARE SAYING..

“My portfolio has grown from 275k to almost 900k with only investments made with Banyan Hill.”

- David G. (Member since 2018)

“Looks like I have finally found the right person to learn and grow from.”

- James

"I couldn’t believe it … in just 2 months, I made $298,506 on one stock – that’s a 24% gain!"

- John B.

Share This